{
  "docId": "019de070-f8c0-72fa-b47b-4b134ca99d3b",
  "docSlug": "4fd785179c9b78e08eb8c823d8e306e6",
  "documentTitle": "argenx SE | Results Presentation Deck | 24 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 24,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "other",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a visual representation of an antibody molecule to map specific proprietary technologies (NHANCE, POTELLIGENT, DHS, ACT-Ig, ABDEG) to the Fc region.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de070-f8c0-72fa-b47b-4b134ca99d3b/16",
  "deckHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b",
  "deckJsonHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b.json",
  "deckAnchorHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.08,
        "y": 0.5
      },
      "kind": "callout",
      "text": "SC Dosing Optionality: Halozyme ENHANZE Technology",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba8133fb-d3da-49ef-9bc9-94d16214eb46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.5,
        "y": 0.29
      },
      "kind": "framework",
      "text": "Fc Engineering to Optimize Antibodies",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9cc9ceb0-411c-4098-92f2-aebfa352ed26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.55,
        "y": 0.09
      },
      "kind": "framework",
      "text": "V-Region Capabilities SIMPLE Antibody Platform",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be27d53f-a1c8-4bfe-b671-a229eb46430d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.85,
        "w": 0.4,
        "x": 0.425,
        "y": 0.11
      },
      "kind": "image",
      "text": "Antibody molecule diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60247697-5015-428e-ab3d-7605fef2a11e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.43,
        "y": 0.4
      },
      "kind": "list",
      "text": "NHANCE, POTELLIGENT, DHS Mutations, ACT-Ig/SMART-Ig, ABDEG",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48aa7900-81a7-4b9d-b566-46e4b1310804",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Leading Antibody Discovery and Engineering Toolkit",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10a4c7db-a694-4de6-8f61-685bb81ded38",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "24fedf50-a656-4183-a937-aa7cc5756d67",
      "evidence": "NHANCE, POTELLIGENT, DHS Mutations, ACT-Ig/SMART-Ig, ABDEG",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 22,
      "from": 13,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "75721239-1041-4fe6-8eab-446d817772cd",
      "evidence": "Slides 13 and 22 discuss the need for new therapies and the potential of Efgartigimod.",
      "position": 0,
      "objective": "Highlighting the cost of inaction for MG patients.",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}